Tyra BiosciencesTYRA +3.07%28 Current Ratio is 20.49 as of Mar. 2026, which is 38% below its 10-year median of 32.84. GuruFocus rates TYRA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Tyra Biosciences ranks better than 92.73% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Tyra Biosciences's current ratio for the quarter that ended in Mar. 2026 was 20.49.
Tyra Biosciences has a current ratio of 20.49. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Tyra Biosciences's Current Ratio or its related term are showing as below:
TYRA'
s Current Ratio Range Over the Past 10 Years
Min: 0.02 Med: 32.84 Max: 84.09
Current: 20.49
During the past 7 years, Tyra Biosciences's highest Current Ratio was 84.09. The lowest was 0.02. And the median was 32.84.
TYRA's Current Ratio is ranked better than 92.73% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs TYRA: 20.49
Tyra Biosciences (NAS:TYRA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Tyra Biosciences Current Ratio Related Terms
Tyra Biosciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Tyra Biosciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TYRA vs ZLAB, OCUL, AUPH: Current Ratio Comparison
For the Biotechnology subindustry, Tyra Biosciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tyra Biosciences Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tyra Biosciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Tyra Biosciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tyra Biosciences (TYRA) has a Current Ratio of 20.49 as of Mar. 2026. This is 38% below median its historical median of 32.84. Over the past decade, Tyra Biosciences' Current Ratio has ranged from 0.02 to 84.09. According to the industry distribution chart, Tyra Biosciences ranks #103 out of 1416 companies in the Biotechnology industry, placing it in the top 7.3%.
Is Tyra Biosciences' Current Ratio too high?
Tyra Biosciences' current Current Ratio of 20.49 is 38% below median its 10-year median of 32.84. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 84.09. The Biotechnology industry median Current Ratio is 3.89. Tyra Biosciences' value of 20.49 is 427.4% above this industry median. Based on the distribution chart, Tyra Biosciences ranks #103 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tyra Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Tyra Biosciences' Current Ratio compare to ZLAB and OCUL?
According to the Biotechnology industry distribution chart, Tyra Biosciences ranks #103 out of 1416 companies for Current Ratio. This places Tyra Biosciences in the top 7% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Tyra Biosciences' value of 20.49 is 427.4% above this benchmark. Historically, Tyra Biosciences' own Current Ratio has ranged from 0.02 to 84.09 over the past decade. While the company's 10-year median is 32.84 vs. the industry median of 3.89, Tyra Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tyra Biosciences's current Current Ratio of 20.49 is 427.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tyra Biosciences's current Current Ratio is 20.49, which is 38% below median its own 10-year median of 32.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyra Biosciences stock overvalued right now?
Tyra Biosciences (TYRA) has a current Current Ratio of 20.49. The current Current Ratio is 20.49, which is 38% below median its 10-year median of 32.84 and 427.4% above the Biotechnology industry median of 3.89. Tyra Biosciences' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Tyra Biosciences (TYRA), the current Current Ratio is 20.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
28GF Score
Get the complete analysis for TYRA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYRA has been successfully added to your 
